直 Japanese PDF Font
  • 我们的专业人员
  • 服务
  • 我们的见解
  • 办公室
  • 事务所
  • 人才招聘
Finnegan
  • 新闻
  • 飞翰事实
  • History
    • Finnegan VISION
    • Finnegan FORWARD
  • 慈善性法律援助
  • 管理层
    • Pricing & Alternative Fee Arrangements
    • AFA Models We Offer
    • Contingency Fees
    • AI + KM

James R. Barney

Nestle Gets Another Chance in Bottling Patent Fight

May 10, 2017

Bloomberg BNA

On May 9, 2017, the Federal Circuit gave Finnegan client Nestle a second chance to challenge Steuben Foods Inc.'s patent on bacteria-free bottling. The court vacated and remanded the Patent Trial and Appeal Board's (PTAB) ruling that Steuben Foods' patent is valid. The determination of the patent's validity is dependent upon the level of how "aseptic" bottles have to be before they are filled. The Federal Circuit agreed with Nestle that the FDA had clear regulations related to packaging and remanded the case for a validity determination in line with Nestle's preferred interpretation.

Tags

United States Court of Appeals for the Federal Circuit (CAFC), Food and Drug Administration (FDA)

Related Practices

专利局无效程序

PTAB无效程序:双方复审及授权后复审

联邦巡回法院和最高法院上诉

Related Industries

消费品

Related News

Award/Ranking

Finnegan Earns Top Rankings in 2026 IAM Patent 1000 Guide; Nearly 60 Attorneys Ranked

May 28, 2026

Commentary

Quince Aims to Have ‘Dupe’ Evidence Shape Ugg Shoe Patent Trial

May 26, 2026

Commentary

New Appellate Opinion in Amazon Biometric Data Case May Signal ‘Narrowing’ Scope of BIPA Litigation, Experts Say

May 20, 2026

Award/Ranking

Finnegan Partner Antje Brambrink Shortlisted for Women in Business Law EMEA Award

May 13, 2026

Press Release

Finnegan Secures Decisive ITC Victory for Innoscience in Final Determination

May 11, 2026

Commentary

ITC Bars Import of Innoscience Chips Made Before Redesign

May 8, 2026

Commentary

How Litigation Funding Disclosure Could Affect ITC Cases

May 7 , 2026

Award/Ranking

Associates Rank Finnegan “Best of the Best” in BTI Associate Satisfaction Survey

May 7, 2026

Commentary

Justices to Side with Generic Drugmakers in Patent Spat, Attorneys Predict

May 5, 2026

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • 隐私
  • 免责申明
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP